18:33 , Nov 30, 2018 |  BC Week In Review  |  Company News

Sinovant gains Chinese rights to Angion's BB3

Angion Biomedica Corp. (Uniondale, N.Y.) granted Sinovant Sciences Ltd. (Beijing, China) exclusive rights to develop, commercialize and manufacture BB3 in China, including Hong Kong and Macau, and Taiwan. Angion will receive an upfront payment and...
20:16 , Feb 16, 2017 |  BC Week In Review  |  Clinical News

BB3: Ph II GUARD started

Angion began the double-blind, placebo-controlled, U.S. Phase II GUARD trial to evaluate 6 mg/mL IV BB3 daily for 4 days in about 100 patients who undergo open heart surgery and require the use of cardiopulmonary...
00:56 , Oct 25, 2014 |  BC Extra  |  Financial News

Angion withdraws IPO

Angion Biomedica Corp. (Uniondale, N.Y.) withdrew its proposed IPO on NASDAQ, citing market conditions. In June, the company amended its IPO to sell 2.7 million shares at $10-$12. At $11, the company would have raised...
01:23 , May 28, 2014 |  BC Extra  |  Financial News

Angion sets IPO terms

Angion Biomedica Corp. (Uniondale, N.Y.) amended its IPO on NASDAQ and now plans to sell 2.7 million shares at $10-$12. At the $11 midpoint, the company would raise $30 million and be valued at $73.1...
23:30 , Apr 15, 2014 |  BC Extra  |  Financial News

Angion files for IPO

Angion Biomedica Corp. (Uniondale, N.Y.) filed to raise up to $34.5 million in an IPO on NASDAQ underwritten by Aegis Capital. Angion's BB3 is in Phase II testing to treat delayed graft function in renal...
07:00 , Jul 23, 2012 |  BC Week In Review  |  Clinical News

BB3: Phase II started

Angion began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate 2 mg/kg IV BB3 daily for 4 days in 80 patients following a first heart attack. The compound has Fast Track and Orphan Drug...
07:00 , May 16, 2011 |  BC Week In Review  |  Company News

Angion, Duke University, Massachusetts General Hospital deal

Angion partnered with the university and the hospital to develop Angion's BB3 for ischemic stroke. The hepatocyte growth factor (HGF) mimetic is in preclinical development for the indication and is in Phase II testing for...
07:00 , Jul 12, 2010 |  BC Week In Review  |  Clinical News

BB3 regulatory update

FDA granted Fast Track and Orphan Drug designations for Angion's BB3 to treat renal transplantation and acute renal failure. The hepatocyte growth factor (HGF) mimetic is in Phase II testing for acute renal failure and...